dm+d

Unassigned

New Medicines

Mild-to-moderate (MMSE 12-24) Alzheimer's disease

Information

New molecular entity
Cortexyme
Cortexyme

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Peptide hydrolase inhibitor, targeting P. gingivalis gingipains
AD is the most common form of dementia. It is estimated to affect 520,000 people in the UK [1]. Porphyromonas gingivalis (P. gingivalis) is one of the several important bacterial pathogens associated with the sporadic AD. All P. gingivalis forms express proteolytically active proteases that enable cleavage of the amyloid-β protin precursor (AβPP) and tau resulting in the formation of amyloid-β and neurofibrillary tangles [5].
Mild-to-moderate (MMSE 12-24) Alzheimer's disease
Oral